Skip to main content
Michael Charlton, MD, Gastroenterology, Chicago, IL, University of Chicago Medical Center

MichaelRCharltonMD

Gastroenterology • Chicago, IL

Hepatology & Liver Transplantation

Director, Transplant Institute, Professor of Medicine, University of Chicago

Join to view full profile

Dr. Charlton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Charlton's full profile

Already have an account?

Summary

  • I am a physician scientist who is American Board of Internal Medicine certified in Gastroenterology and Hepatology and Transplant Hepatology. I attained the rank of Professor of Medicine at Mayo Clinic, where I served as Chief of Hepatology and Medical Director of Liver Transplantation. I subsequently served as Director of Transplantation and Regenerative Medicine at Intermountain Healthcare. I am currently Chief of Hepatology and Medical Director of the Transplant Institute at the University of Chicago. I received training in basic and translational research methods through the NIH GCRC-based CAP program and have been principal investigator on multiple NIH grants, including as principal investigator on an RO1. I have also served as lead and principal investigator in many clinical trials sponsored by NIH and industry. I was selected to serve on a multisociety panel of experts to develop a widely utilized set of guidelines for the management of non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH) and also for hepatitis C infection, directing two sections. I am past -president of International Liver Transplant Society. My translational research has focused on HCV and NAFLD/NASH. My basic research has consistently focused on NAFLD, building on early NIH-sponsored career training grant in the Mayo Clinic Center for Clinical and Translational Science (CCaTS) and in the Mayo Clinic Endocrine Research Unit, experiences that have proved invaluable in studying fatty liver disease. My current basic research focus is on the role of the microbiome in dietary-induced fibrosing NASH, in experiments that utilize the animal model developed in my lab. This work is being conducted in the University of Chicago’s Duchossois Family Institute, an internationally renowned center devoted to the study of the microbiome. I also continue translational studies and publications utilizing national databases.

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Transplant Hepatology, 1994 - 1995
  • University of Vermont Medical Center
    University of Vermont Medical CenterFellowship, Gastroenterology, 1992 - 1994
  • University of Vermont Medical Center
    University of Vermont Medical CenterResidency, Internal Medicine, 1990 - 1992
  • Charing Cross and Westminister Medical School
    Charing Cross and Westminister Medical SchoolClass of 1986

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2017 - 2026
  • UT State Medical License
    UT State Medical License 2013 - 2020
  • MN State Medical License
    MN State Medical License 1995 - 2014
  • VT State Medical License
    VT State Medical License 1990 - 1994
  • American Board of Internal Medicine Gastroenterology
  • American Board of Internal Medicine Transplant Hepatology

Awards, Honors, & Recognition

  • President International Liver Transplant Society, 2015
  • Associate Editor Hepatology, 2006-2010
  • Fellow of the Royal College of Physicians Royal College of Physicians, 2008
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • CBD May Increase the Adverse Effects of THC in Edible Cannabis Products, Study Shows
    CBD May Increase the Adverse Effects of THC in Edible Cannabis Products, Study ShowsFebruary 12th, 2023
  • UChicago Medicine Celebrates 2022 Transplant Milestones
    UChicago Medicine Celebrates 2022 Transplant MilestonesFebruary 12th, 2023
  • Enzychem Lifesciences Appoints Dr. Michael Charlton to Its Scientific Advisory Board
    Enzychem Lifesciences Appoints Dr. Michael Charlton to Its Scientific Advisory BoardJanuary 28th, 2020
  • Join now to see all

Grant Support

  • Pathophysiology And Characterisation Of NafldNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2009
  • Body Composition In Cirrhosis: Compare With Nutritional Status And Outcome PredicNational Center For Research Resources2000–2002
  • VLDL Apo-B-100 Synthesis In Non-Alcoholic SteatohepatitisNational Center For Research Resources1998–2002
  • Effect Of Cirrhosis On Protein MetabolismNational Center For Research Resources1996–2002
  • Mucosal Protein Synthesis In Type I Diabetes MellitusNational Center For Research Resources1997–1999
  • Reduction Of HCV Recurrance After Liver TransplantationNational Institute Of Diabetes And Digestive And Kidney Diseases1998

Hospital Affiliations

Dr. Michael Charlton, Dr. Michael Charlton, MD, Dr. M Charlton, Dr. Michael R Charlton